The long term goal of this project is to improve the metabolic complications of hyperinsulinemia in patients with polycystic ovary syndrome, hypertriglyceridemia, metabolic syndrome and type 2 diabetes mellitus by better understanding the newly-recognized dietary component pinitol. Pinitol (3-O-methyl-D-chiro-inositol) is a sugar related to myo-inositol, which is found in mammalian mediator molecules. Pinitol and its demethylated product D-chiro-inositol have been identified in small molecular weight bioactive inositol glycans from several different signaling pathways, including some related to insulin action. Treatment of patients with D-chiro-inositol or pinitol has been found to reduce insulin levels, lower hemoglobin Alc, lower elevated serum testosterone and reduce serum triglycerides in hyperinsulinemic patients. Our laboratory has established that pinitol, while very low in most foods, is a major component of legumes and citrus fruits, and that diet is a major contributor to body inositol levels. Pinitol is enzymatically converted to D-chiro-inositol in humans. We have developed a highly-sensitive inositol assay using gas chromatography/negative ion mass spectrometry that allows measurement of picomole amounts in serum and urine. The proposed work will test the hypothesis that, in human subjects, dietary pinitol administration elevates plasma pinitol and D-chiro-inositol levels and reduces plasma insulin, plasma free fatty acids and triglycerides. The kinetics of these inositols will be studied using specially-prepared deuterated tracers. This work will provide basic information about pinitol consumption, metabolism, kinetics and metabolic effects in hyperinsulinemic subjects. In the long term it may be possible to improve human hyperinsulinemic states by dietary recommendations or by recovering pinitol from food waste streams.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK058698-01A2
Application #
6578642
Study Section
Metabolism Study Section (MET)
Program Officer
Laughlin, Maren R
Project Start
2002-09-30
Project End
2005-08-31
Budget Start
2002-09-30
Budget End
2003-08-31
Support Year
1
Fiscal Year
2002
Total Cost
$265,385
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Lin, Xiaobo; Ma, Lina; Gopalan, Chaya et al. (2009) d- chiro-Inositol is absorbed but not synthesised in rodents. Br J Nutr 102:1426-34
Lin, Xiaobo; Ma, Lina; Fitzgerald, Robin L et al. (2009) Human sodium/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells. Arch Biochem Biophys 481:197-201
Baillargeon, Jean-Patrice; Nestler, John E; Ostlund, Richard E et al. (2008) Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 23:1439-46
Cheang, Kai I; Baillargeon, Jean-Patrice; Essah, Paulina A et al. (2008) Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 57:1390-7
Baillargeon, Jean-Patrice; Diamanti-Kandarakis, Evanthia; Ostlund Jr, Richard E et al. (2006) Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 29:300-5